comparemela.com

Latest Breaking News On - ஃபார்‌பர் புற்றுநோய் நிறுவனம் - Page 8 : comparemela.com

Stop & Shop Kicks Off Annual Help Cure Childhood Cancer Campaign

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Stop & Shop Kicks Off Annual ‘Help Cure Childhood Cancer’ Campaign Stop and ShopMarch 1, 2021 GMT QUINCY, Mass., March 01, 2021 (GLOBE NEWSWIRE) Stop & Shop today announced the start of its annual ‘Help Cure Childhood Cancer’ campaign to support Dana-Farber Cancer Institute and the Jimmy Fund in Massachusetts and MSK Kids, the Pediatrics Program at Memorial Sloan Kettering Cancer Center in New York. Since the campaign’s inception decades ago, Stop & Shop and its customers have contributed more than $100 million to these two hospitals, allowing them to make significant advancements in pediatric cancer research and care.

Dana-Farber announces initiatives for Colorectal Cancer Awareness month in March

Dana-Farber, Broad Institute and Count Me In receive $16 million grant to launch patient-partnered research initiatives

Date Time Share Dana-Farber, Broad Institute and Count Me In receive $16 million grant to launch patient-partnered research initiatives Funding from the National Cancer Institute will help optimize patient engagement in research while studying osteosarcoma and leiomyosarcoma Dana-Farber Cancer Institute, The Broad Institute of MIT and Harvard, and Count Me In, a non-profit research initiative that conducts patient-partnered studies of cancer, have been awarded a new $16 million grant from the National Cancer Institute, to accelerate research in two rare forms of cancer. The funding will support research projects in leiomyosarcoma and osteosarcoma, two cancers which have seen few recent therapeutic advances, while simultaneously yielding new information about the best ways to engage with patients traditionally underrepresented in cancer research. The goal of these projects is to accelerate discoveries that can drive new insights into the genomic roots of rare cancer, discover mec

Harvard s Wyss Institute collaborates with GBS Inc on the Wyss eRapid-based COVID-19 diagnostic to help curb the pandemic

Share this article Share this article BOSTON, Feb. 17, 2021 /PRNewswire/  The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications. The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.